{
    "nctId": "NCT00077025",
    "briefTitle": "Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer",
    "officialTitle": "Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex\u2122)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA\u2122) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 174,
    "primaryOutcomeMeasure": "Time to progression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female postmenopausal patients aged 18 years or older with newly diagnosed metastatic breast cancer.\n* Patients with recurrent disease during or after adjuvant tamoxifen or patients who are hormone therapy na\u00efve are eligible for this trial.\n* A paraffin embedded tumor tissue block or slides from either the metastatic or primary tumor site is required.\n\nExclusion Criteria:\n\n* Patients cannot be on hormone replacement therapy while on study.\n* Prior chemotherapy received for metastatic disease is not allowed.\n* Previous treatment with tyrosine kinase inhibitors or aromatase inhibitors is not allowed.\n* Patients who have evidence of an active interstitial lung disease are not eligible.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}